nfcol.net Neurofibromatosis Clinical Reference · EN / ES
NF1 Criteria NF2 & SWN MEK Therapy Checkup Schedule Archive
EN · Español
Clinical Handbook › Oral MEK1/2 Inhibitors

Selumetinib (Koselugo) vs Mirdametinib (Gomekli): Oral MEK1/2 Guide

Side-by-side comparison of SPRINT, KOMET, and ReNeu clinical trial outcomes, continuous versus 21/7 intermittent dosing schedules, pediatric dispersible formulations, and mandatory cardiac and retinal safety checks.

FDA Approvals: Selumetinib (2020 Pediatric / Adult Expansion) & Mirdametinib (Feb 2025)
Neuroradiology and neuro-oncology specialists reviewing sagittal spinal and cranial MRI scans on a diagnostic display

1. When Oral MEK1/2 Blockade Is Indicated in NF1

Therapeutic Standard: Oral selective MEK1/2 inhibitors—selumetinib (Koselugo) and mirdametinib (Gomekli)—are indicated for pediatric (aged 2 years and older) and adult NF1 patients with symptomatic, inoperable plexiform neurofibromas causing pain, motor dysfunction, airway/orbital compromise, or progressive disfigurement.

Plexiform neurofibromas develop in 30% to 50% of individuals with NF1 due to biallelic loss of neurofibromin in Schwann-cell precursors, unleashing hyperactive RAS–RAF–MEK–ERK signaling. Neither drug is recommended for completely asymptomatic, stable plexiform lesions discovered incidentally, nor are MEK inhibitors active against malignant peripheral nerve sheath tumors (MPNST)—which must be excluded via 18F-FDG PET/CT whenever nocturnal pain or induration is present (Gross et al., 2020; Moertel et al., 2024).

Selumetinib (Koselugo) · 25 mg/m² twice daily Days 1–28 Continuous 12345678910111213141516171819202122232425262728 Mirdametinib (Gomekli) · 2 mg/m² twice daily Days 1–21 Active / Days 22–28 Rest 12345678910111213141516171819202122232425262728
Figure 1. 28-day dosing schedules. Selumetinib maintains continuous twice-daily blockade across all 28 days, whereas mirdametinib administers active therapy on Days 1–21 followed by a 7-day treatment-free rest window (Days 22–28).

2. Head-to-Head Formulary Comparison: Selumetinib vs Mirdametinib

Clinical Parameter Selumetinib (Koselugo) Mirdametinib (Gomekli)
FDA-Approved Population Pediatric (≥2 yr; pediatric granules ≥1 yr in select regions) & Adult symptomatic inoperable NF1 PN (SPRINT & Phase III KOMET) Adults & Children (≥2 yr) with symptomatic inoperable NF1 PN (FDA approved February 11, 2025 based on ReNeu trial)
Standard BSA Dose & Cycle 25 mg/m² orally twice daily, 28/28 days continuous 2 mg/m² orally twice daily (max 4 mg BID), 21 days on / 7 days off
Child-Friendly Formulation 10 mg & 25 mg intact capsules (cannot chew or open; oral granule sprinkles rolling out) 1 mg & 2 mg capsules OR 1 mg tablet for oral suspension (disperses cleanly in drinking water for young children or dysphagia)
Food Effect Updated FDA label permits dosing with or without food (eliminating legacy fasting burden) Taken with or without food
Confirmed Volumetric ORR (≥20% 3D MRI Shrinkage) 68% in SPRINT pediatric cohort; statistically significant adult response in KOMET 52% in children and 41% in adults (ReNeu blinded central 3D volumetric review), with deep responses (>50% shrinkage) in long-term responders

3. Mandatory Safety Surveillance & Rash Prophylaxis

Both MEK1/2 inhibitors share a well-characterized class safety profile that is manageable with proactive supportive care rather than premature treatment discontinuation:

  • Cardiac Left Ventricular Ejection Fraction (LVEF): Obtain baseline echocardiogram before Cycle 1, repeat every 3 months during the first year (or every 3–6 months per label), then every 6 months. Asymptomatic Grade 2 LVEF drops (≥10% decline below lower limit of normal) typically resolve after brief dose interruption.
  • Ophthalmic Retinal Toxicity (RPED / RVO): Perform dilated funduscopy and retinal OCT at baseline, 3 months, 6 months, and every 6–12 months thereafter to detect serous retinal pigment epithelial detachment (RPED) before visual acuity changes.
  • Dermatologic & Paronychia Kit: Acneiform rash (more frequent in post-pubertal adolescents and adults) and nail-fold paronychia peak in Cycles 1–3. Prescribe fragrance-free ceramide emollients, broad-spectrum sunscreen, low-potency topical hydrocortisone/clindamycin from Day 1, and prophylactic oral doxycycline/minocycline in patients aged ≥8 years when indicated; antiseptic vinegar or chlorhexidine nail soaks curb paronychia.
  • Creatine Phosphokinase (CPK) & GI Care: Check serum CPK and liver transaminases prior to treatment and periodically; asymptomatic CPK elevation is common with MEK blockade and rarely reflects true rhabdomyolysis unless paired with myalgia or dark urine.

Frequently Asked Clinical Questions

How long does it take for Koselugo or Gomekli to shrink a plexiform neurofibroma?

Pain relief and motor improvement often begin within 2 to 4 cycles (2–4 months), whereas reaching a formal 20% or greater volumetric reduction on 3D MRI typically takes 4 to 8 cycles (median 7–8 months).

Do patients still have to fast before and after taking selumetinib (Koselugo)?

No. Following pharmacokinetic food-effect studies, the FDA updated the Koselugo label to allow administration with or without food, greatly simplifying twice-daily dosing for school-age children.

Key Consensus Guidelines & Primary Sources

  1. Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine. 2021;23(8):1506–1513. PubMed 34012067.
  2. Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genetics in Medicine. 2022;24(9):1967–1977. PubMed 35674741.
  3. Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas (SPRINT Phase II). New England Journal of Medicine. 2020;382(15):1430–1442. PubMed 32187457.
  4. Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: A pivotal phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. Journal of Clinical Oncology. 2025;43(7):758–769. PubMed 39514828.
  5. Miller DT, Freedenberg D, Schorry E, et al. Health supervision for children with neurofibromatosis type 1 (American Academy of Pediatrics). Pediatrics. 2019;143(5):e20190660. PubMed 30988031.